CSIMarket
 
Soligenix inc   (SNGX)
Other Ticker:  
 
 
Price: $0.6200 $-0.02 -2.638%
Day's High: $0.6911 Week Perf: -15.83 %
Day's Low: $ 0.62 30 Day Perf: -10.97 %
Volume (M): 96 52 Wk High: $ 4.20
Volume (M$): $ 59 52 Wk Avg: $0.78
Open: $0.64 52 Wk Low: $0.38



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Soligenix Inc
Soligenix, Inc. is a biopharmaceutical company that focuses on developing and commercializing products to treat rare diseases with unmet medical needs. The company primarily works on developing therapies for areas such as inflammation, oncology, and infectious diseases. Soligenix's main product candidates include a vaccine for the prevention of ricin toxin exposure (RiVax'), a treatment for oral mucositis in head and neck cancer patients (SGX942), and a treatment for pediatric Crohn's disease (SGX203). The company also has a proprietary technology platform called Dusquetide, which enhances the efficacy of existing drugs. Soligenix is headquartered in Princeton, New Jersey, and was founded in 198


   Company Address: 29 EMMONS DRIVE PRINCETON 8540 NJ
   Company Phone Number: 538-8200   Stock Exchange / Ticker: NASDAQ SNGX
   SNGX is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Soligenix Inc

Soligenix Inc witnesses an impressive revenue surge in Q1 2023, showcasing robust growth

Soligenix Inc is a healthcare company that has recently released its fiscal period financial results. These results show that the company experienced a significant increase in diminishing returns, with a per share value of -$0.36, compared to -$0.06 in the previous year. However, the company's EPS improved from -$4.14 per share in the preceding reporting season.
One positive aspect of Soligenix Inc's financial performance is the strong growth in revenue, which rose by 74.248% to $0.26 million from $0.15 million in the same reporting season a year prior. Additionally, the company's revenue turned positive from -$1,772.95 million sequentially. Despite these improvements, Soligenix Inc realized a net shortfall of -$1.046 million in the most recent fiscal period, instead of achieving balanced books as it did in the same reporting season a year before.

Soligenix Inc

Soligenix Inc Reports Disappointing Financial Results: Deficit Doubles in Most Recent Fiscal Period

Over the past week, Soligenix Inc stock has experienced a slight drop of -0.2%. This decline adds to the year-to-date performance, which currently stands at -6.15%. Despite this recent decrease, the stock is still trading 19.8% higher than its 52-week low.
The drop in Soligenix Inc's stock price can be attributed to lower revenue, which has resulted in diminishing returns in the most recent fiscal period. Revenue decreased by -3.675% to $0.21 million, and the deficit per share was reported at $-0.26. This is a significant difference from the $-0.05 per share realized in the same quarter of the previous year.






 

Soligenix Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com